BCL2 and T-cell non-Hodgkin lymphoma: Chidamide inhibits Myc and BCL2 in acute myeloid leukemia (Li et al. 2015), and its combination with doxorubicin in treating T-cell lymphoma also downregulates BCL2 (Zhang et al. 2017).